Finance

Beta
Lists
CLDX:NASDAQ
Celldex Therapeutics Inc
$38.66
+3.26%
(+1.22) 1D
Jun 30, 11:50:52 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CLDX...
Open
$37.42
High
$39.16
Low
$37.42
Mkt. cap
3.03B
Avg. vol.
1.05M
Volume
689.92K
52-wk high
$39.16
52-wk low
$19.52
EPS
-$4.27
Beta
0.95
Shares outstanding
78.49M
No. of employees
198
Open
$37.42
High
$39.16
Low
$37.42
Mkt. cap
3.03B
Avg. vol.
1.05M
Volume
689.92K
52-wk high
$39.16
52-wk low
$19.52
EPS
-$4.27
Beta
0.95
Shares outstanding
78.49M
No. of employees
198
News stories
From sources across the web
About Celldex Therapeutics Inc
CEO-
Employees198
Founded1983
HeadquartersHampton, New Jersey, United States
SectorBiotechnology
Websitecelldex.com
Analyst ratings
Based on 11 analysts giving stock ratings to CLDX in the past 3 months
Strong buy
Buy
10
Hold
1
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for CLDX in the last 3 months.
Highest
Current $38.66
$67.00 (+73.31%)
Average
$51.10 (+32.18%)
Lowest
$38.00 (-1.71%)
Analyst
Recommendation
Action
Price target
Projected
Date
Derek Archila
Wells Fargo
Buy
Reiterated
$54.00
+39.7%
06/30/2026
David Dai
UBS
Buy
Maintained
$45.00
+16.4%
06/16/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$67.00
+73.3%
06/14/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$67.00
+73.3%
06/15/2026
Andy Chen
Wolfe Research
Buy
Maintained
$44.00
+13.8%
06/14/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$42.00
+8.6%
06/15/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
$44.00
+13.8%
06/12/2026
Richard Law CFA
Goldman Sachs
Hold
Maintained
$38.00
-1.7%
05/08/2026
Edward Nash
Canaccord Genuity
Buy
Maintained
$62.00
+60.4%
05/08/2026
Etzer Darout
Barclays
Buy
Reiterated
$48.00
+24.2%
05/08/2026
Yaron Werber
TD Cowen
Buy
Maintained
-
-
05/07/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$68.00
+75.9%
02/26/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$90.00
+132.8%
02/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
730.00K
-
121.00K
15.00K
Cost of goods sold
54.20M
62.93M
75.33M
73.00M
Cost of revenue
54.20M
62.93M
75.33M
73.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.39M
10.69M
11.94M
11.45M
Operating expense
10.39M
10.69M
11.94M
11.45M
Total operating expenses
64.59M
73.62M
87.27M
84.45M
Operating income
-63.86M
-73.62M
-87.15M
-84.44M
Other non operating income
-
-
-
-
EBT including unusual items
-56.60M
-67.04M
-81.32M
-78.68M
EBT excluding unusual items
-56.60M
-67.04M
-81.32M
-78.68M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-56.60M
-67.04M
-81.32M
-78.68M
Net profit margin
-7,753.42%
-
-67,204.13%
-524,566.67%
Earnings per share
-0.85
-1.01
-1.22
-1.18
Interest and investment income
7.26M
6.57M
5.84M
5.75M
Interest expense
-
-
-
-
Net interest expenses
7.26M
6.57M
5.84M
5.75M
Depreciation and amortization charges
-
-
-
-
EBITDA
-62.98M
-72.79M
-86.34M
-83.58M
Gain or loss from assets sale
2.00K
6.00K
-
3.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer